-
公开(公告)号：US20220185900A1
公开(公告)日：2022-06-16
申请号：US17602562
申请日：2020-04-09
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Christopher Daly , Gavin Thurston , Nicholas Papadopoulos
IPC: C07K16/28 , A61P35/00 , A61K45/06 , A61K39/395
Abstract: The present invention provides fully human antibodies that bind to the RET receptor tyrosine kinase, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for treating diseases, disorders, or conditions associated with expression, activation, or signaling of the RET receptor tyrosine kinase gene, or a rearranged form thereof, including cancerous conditions and the pain associated with the cancer, or for alleviating the pain associated with other conditions attributed to, at least in part, by expression, activation or signaling of RET. The antibodies specific for RET may be useful for slowing tumor cell growth or tumor cell proliferation and also for alleviating the pain associated with the cancer and other conditions. The antibodies may also be useful for diagnosis of a disease, disorder or condition associated with RET activation or signaling.
-
公开(公告)号：US09116159B2
公开(公告)日：2015-08-25
申请号：US13900129
申请日：2013-05-22
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Nicholas Papadopoulos , Anthony Dore , Douglas MacDonald
CPC classification number: G01N33/74 , C07K14/71 , C07K16/22 , C07K2319/30 , G01N2333/515 , G01N2800/52
Abstract: The invention provides a method for determining the level of VEGF-A121 isoform in a sample by selectively removing the VEGF-A165 isoform from the sample using a neuropilin-1 pull-down procedure, then determining the total amount of VEGF-A remaining afterward. The invention provides methods of treating a patient suffering from a disease which may benefit from the administration of a VEGF antagonist by determining the level of VEGF-A121 in the patient's circulation. Methods of diagnosis, prognosis, monitoring, and patient stratification are also provided.
Abstract translation: 本发明提供了一种通过使用神经丝氨酸-1下拉法从样品中选择性除去VEGF-A165同种型，然后测定其后剩余的VEGF-A总量来确定样品中VEGF-A121同种型水平的方法。 本发明提供了通过测定患者血液循环中VEGF-A121的水平来治疗患有可能受益于VEGF拮抗剂的疾病的患者的方法。 还提供了诊断，预后，监测和患者分层的方法。
-
公开(公告)号：US09459263B2
公开(公告)日：2016-10-04
申请号：US14811056
申请日：2015-07-28
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Nicholas Papadopoulos , Anthony Dore , Douglas MacDonald
CPC classification number: G01N33/74 , C07K14/71 , C07K16/22 , C07K2319/30 , G01N2333/515 , G01N2800/52
Abstract: The invention provides a method for enriching the level of VEGF-A121 isoform in a sample by selectively removing the VEGF-A165 isoform from the sample using a neuropilin-1 pull-down procedure, then determining the total amount of VEGF-A remaining afterward. The invention provides methods of treating a patient suffering from a disease which may benefit from the administration of a VEGF antagonist by determining the level or ratio of VEGF-A121 in the patient's circulation. Methods of diagnosis, prognosis, monitoring, and patient stratification are also provided.
Abstract translation: 本发明提供了通过使用神经丝氨酸-1下拉法从样品中选择性除去VEGF-A165同种型，然后确定其后剩余的VEGF-A的总量，从而提高样品中VEGF-A121同种型水平的方法。 本发明提供了通过确定患者循环中VEGF-A121的水平或比例来治疗患有可能受益于VEGF拮抗剂的患者的患者的方法。 还提供了诊断，预后，监测和患者分层的方法。
-
Patent Agency Ranking
公开(公告)号：US20220008548A1
公开(公告)日：2022-01-13
申请号：US17483588
申请日：2021-09-23
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC: A61K47/68 , C07K16/22 , C07K16/28 , C07K16/32 , C12N9/64 , C07K16/12 , C07K16/18 , C07K14/47 , C07K16/30 , A61P35/00 , C07K16/46
Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号：US20190000984A1
公开(公告)日：2019-01-03
申请号：US15738801
申请日：2016-07-06
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
Abstract: The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the disclosure, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号：US12297257B2
公开(公告)日：2025-05-13
申请号：US17483588
申请日：2021-09-23
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC: C07K16/12 , A61K39/00 , A61K47/68 , A61P35/00 , C07K14/47 , C07K16/18 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/46 , C12N9/64
Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号：US11191844B2
公开(公告)日：2021-12-07
申请号：US15738801
申请日：2016-07-06
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC: A61K47/68 , C07K16/22 , C07K16/28 , C07K16/32 , C07K16/18 , C07K14/47 , C07K16/30 , A61P35/00 , C07K16/46 , A61K39/00 , C12N9/64 , C07K16/12
Abstract: The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the disclosure, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure causes or facilitates the targeted killing of tumor cells.
-
公开(公告)号：US11129903B2
公开(公告)日：2021-09-28
申请号：US15202822
申请日：2016-07-06
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Julian Andreev , Nithya Thambi , Frank Delfino , Joel Martin , Gavin Thurston , Katherine Cygnar , Nicholas Papadopoulos
IPC: A61K47/68 , C07K16/22 , C07K16/28 , C07K1/32 , C07K16/12 , C07K16/18 , C07K14/47 , C07K16/30 , A61P35/00 , C07K16/46 , A61K39/00 , C12N9/64 , C07K16/32
Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.015 seconds)
